MedGene Therapeutics, Inc.
Steve Yoo serves as the Chief Financial Officer at MedGene Therapeutics, Inc. since 2022. Prior to this role, Steve was a General Partner at PhiFund from 2021 to 2022 and held the position of Senior Analyst at Sofinnova from 2017 to 2020. Earlier experience includes positions as an Analyst at Surveyor Capital (2014-2016) and US FP&A Aranesp at Amgen (2013-2014). Steve also worked as Vice President at Leerink Swann (2008-2012), Associate Analyst at UBS (2007-2008), and Research Associate at Sanford C. Bernstein from October 2005 to March 2007, specializing in the Biotech team. Steve holds a Bachelor of Science degree in Biology from the Massachusetts Institute of Technology.
This person is not in any teams
This person is not in any offices
MedGene Therapeutics, Inc.
MedGene Therapeutics is focused on developing ACT treatments (PMBC derived tumor-reactive T cells-Natural Unmodified CD8+ lymphocytes) for two cancers—MSTS (metastatic soft tissue sarcoma) and MFTC (metastatic follicular thyroid cancer)—using NIH patented technology with Worldwide Exclusive License Agreement of commercialization.